Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E
ApprovedActive 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Critical Illness
Conditions
Critical Illness, Starvation
Trial Timeline
Aug 1, 2007 → Dec 1, 2026
NCT ID
NCT00512122About Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E
Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E is a approved stage product being developed by Baxter for Critical Illness. The current trial status is active. This product is registered under clinical trial identifier NCT00512122. Target conditions include Critical Illness, Starvation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00512122 | Approved | Active |
Competing Products
13 competing products in Critical Illness
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin | Merck | Approved | 85 |
| Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose | Merck | Phase 1 | 33 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Amgen | Approved | 84 |
| intensive insulin therapy to maintain normoglycemia | Novo Nordisk | Phase 2 | 51 |
| Midazolam + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Apixaban + ASA + Clopidogrel 75mg | Pfizer | Phase 3 | 76 |
| Colchicine (Colcrys®) + placebo + allopurinol | Regeneron Pharmaceuticals | Approved | 84 |
| Rilonacept 80 mg + Rilonacept 160 mg | Regeneron Pharmaceuticals | Phase 3 | 76 |
| treprostinil dienthanolmine sustained release + Placebo | United Therapeutics | Phase 2 | 49 |
| Remodulin® (treprostinil sodium) Injection | United Therapeutics | Phase 3 | 74 |
| Olimel (5.7%E / N9E) | Baxter | Phase 3 | 74 |
| RJX + Placebo | ICON plc. | Phase 1 | 30 |
| Ixmyelocel-T | Vericel | Phase 3 | 72 |